Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Day One Biopharmaceuticals ( (DAWN) ) has shared an update.
On October 7, 2025, Day One Biopharmaceuticals‘ Board of Directors approved a repricing of stock options for certain directors and employees, including executive officers, to retain and motivate key contributors without incurring additional equity grants or cash expenditures. The repricing adjusts the exercise price of options to the closing price of the company’s stock on the effective date, with conditions for service retention and specific terms for executive officers.
The most recent analyst rating on (DAWN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a company in the biopharmaceutical industry, focusing on developing and commercializing targeted therapies for patients of all ages with life-threatening diseases, particularly in oncology.
Average Trading Volume: 1,546,847
Technical Sentiment Signal: Hold
Current Market Cap: $774.4M
See more insights into DAWN stock on TipRanks’ Stock Analysis page.